TY - JOUR T1 - Rapid Detection of SARS-CoV-2 Using Reverse transcription RT-LAMP method JF - medRxiv DO - 10.1101/2020.03.02.20030130 SP - 2020.03.02.20030130 AU - Weihua Yang AU - Xiaofei Dang AU - Qingxi Wang AU - Mingjie Xu AU - Qianqian Zhao AU - Yunying Zhou AU - Huailong Zhao AU - Li Wang AU - Yihui Xu AU - Jun Wang AU - Shuyi Han AU - Min Wang AU - Fenyan Pei AU - Yunshan Wan Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/03/2020.03.02.20030130.abstract N2 - Corona Virus Disease 2019 (COVID-19) is a recently emerged life-threatening disease caused by SARS-CoV-2. Real-time fluorescent PCR (RT-PCR) is the clinical standard for SARS-CoV-2 nucleic acid detection. To detect SARS-CoV-2 early and control the disease spreading on time, a faster and more convenient method for SARS-CoV-2 nucleic acid detecting, RT-LAMP method (reverse transcription loop-mediated isothermal amplification) was developed. RNA reverse transcription and nucleic acid amplification were performed in one step at 63 °C isothermal conditions, and the results can be obtained within 30 minutes. ORF1ab gene, E gene and N gene were detected at the same time. ORF1ab gene was very specific and N gene was very sensitivity, so they can guarantee both sensitivity and specificity for SARS-CoV-2. The sensitivity of RT-LAMP assay is similar to RT-PCR, and specificity was 99% as detecting 208 clinical specimens. The RT-LAMP assay reported here has the advantages of rapid amplification, simple operation, and easy detection, which is useful for the rapid and reliable clinical diagnosis of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOVID-19 prevention and control project of JinanAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll authors agree that all data submitted here are publicly available. ER -